{
    "clinical_study": {
        "@rank": "154857", 
        "acronym": "PC1", 
        "arm_group": {
            "arm_group_label": "G17DT", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study was designed to determine the effect of jaundice on the ability of G17DT to\n      generate antibodies before and after treatment of biliary obstruction due to advanced\n      pancreatic cancer."
        }, 
        "brief_title": "An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma", 
        "completion_date": {
            "#text": "February 2002", 
            "@type": "Actual"
        }, 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histological or cytological confirmation of pancreatic carcinoma who\n             were not suitable for pancreatic tumour resection with curative intent\n\n          -  Patients who had not received chemotherapy in the previous month and who would either\n             not receive chemotherapy in the period of study or who would commence gemcitabine\n             treatment in week 4 of the study\n\n          -  Male or female patients over 18 years of age\n\n          -  Patients with a life expectancy of at least 2 months\n\n          -  Patients must have given written informed consent\n\n          -  Patients with a Karnofsky Performance Status score of \u2265 50%\n\n          -  Patients who would not receive chemotherapy in the period of the Extension Survival\n             Study, except for concomitant gemcitabine ongoing at visit (for extension study)\n\n        Exclusion Criteria:\n\n          -  History of other malignant disease except non-melanomatous skin carcinoma or in situ\n             carcinoma of the uterine cervix\n\n          -  Concomitant use or anticipated use in the period of the study of radiotherapy\n\n          -  Chemotherapy in the previous month preceding screening, anticipated concomitant use\n             of chemotherapy between screening and week 4 of the study or anticipated useof\n             chemotherapeutic agents other than gemcitabine from week 4 for the period of the\n             study\n\n          -  Use in the past month or concomitant use of immunosuppressants, including systemic\n             (i.e. oral or injected) corticosteroids\n\n          -  Females who were pregnant, planning to become pregnant or lactating\n\n          -  Patients taking part in another study involving an investigational or licensed drug\n             or device in the three months preceding enrolment or during the study\n\n          -  Haematological indicators:\n\n        Haemoglobin <9.5g/dl White blood cell count <3.5 x 109/l Platelets <100 x 109/l"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02098291", 
            "org_study_id": "PC1"
        }, 
        "intervention": {
            "arm_group_label": "G17DT", 
            "intervention_name": "G17DT", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 26, 2014", 
        "number_of_arms": "1", 
        "official_title": "Phase II, Open, Single-center Study to Determine the Antibody Response to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2001", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Anti-Gastrin 17 antibodies were determined at baseline (week0) and measured at subsequent visits during the first 16 weeks after the first G17DT injection to determine the effect of jaundice on the ability of patients to generate antibodies.", 
            "measure": "Pharmacodynamic", 
            "safety_issue": "No", 
            "time_frame": "Up to week 16"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02098291"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The vital status was monitored throughout the study and was followed up to the death of the last patient.", 
                "measure": "Patient Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to week 139"
            }, 
            {
                "description": "Adverse events, defined as any event involving adverse reactions, illnesses with onset during the study, or exacerbations of pre-exisiting illnesses, were assessed at each visit.", 
                "measure": "Number of Participants with Serious and Non-Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to week 60"
            }
        ], 
        "source": "Cancer Advances Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cancer Advances Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 1999", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}